GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Debt-to-Asset

Evolus (FRA:EVL) Debt-to-Asset : 0.57 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evolus Debt-to-Asset?

Evolus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1.4 Mil. Evolus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €115.6 Mil. Evolus's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €206.9 Mil. Evolus's debt to asset for the quarter that ended in Sep. 2024 was 0.57.

Evolus Debt-to-Asset Historical Data

The historical data trend for Evolus's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Debt-to-Asset Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.40 0.66 0.29 0.42 0.67

Evolus Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.67 0.56 0.54 0.57

Competitive Comparison of Evolus's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolus's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Evolus's Debt-to-Asset falls into.


Evolus Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Evolus's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.263 + 114.78) / 173.311
=0.67

Evolus's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.443 + 115.575) / 206.877
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus  (FRA:EVL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Evolus Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Evolus's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Debt-to-Asset
Comparable Companies
PAHC HROW SIGA PETQ PROC BKUH ORGO AMRX LFCR RGC ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
EOLS:USA 0K16:UK
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Website
https://www.evolus.com
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines